Inventor · disambiguated record
Mads Hald Andersen
Also filed as: ANDERSEN MADS HALD
24 granted patents·21 pending applications·49 citations·filing 2003–2025
94Inventor score
Top patents by PatentIndex Score
45 records- 0194US11447537B2PDL2 compoundsIO BIOTECH APS·Filed 2020·Granted Sep 20, 2022·3 cites·8 claims
- 0294US10858642B2Immunogenic arginase peptidesIO BIOTECH APS·Filed 2017·Granted Dec 8, 2020·7 cites·29 claims
- 0391US11648302B2Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2022·Granted May 16, 2023·1 cites·19 claims
- 0488US11298413B2Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereofIO BIOTECH APS·Filed 2016·Granted Apr 12, 2022·3 cites·5 claims
- 0586US11981944B2Immunogenic arginase peptidesIO BIOTECH APS·Filed 2020·Granted May 14, 2024·1 cites·13 claims
- 0685US12233103B2Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2023·Granted Feb 25, 2025·0 cites·19 claims
- 0785US11324813B2Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2019·Granted May 10, 2022·1 cites·18 claims
- 0885US2025236658A1Pdl2 compoundsIO BIOTECH APS·Filed 2024·Application pending·0 cites
- 0983US9433666B2Indoleamine 2,3-dioxygenase based immunotherapyANDERSEN MADS HALD·Filed 2009·Granted Sep 6, 2016·4 cites·2 claims
- 1081US12215135B2PDL2 compoundsIO BIOTECH APS·Filed 2022·Granted Feb 4, 2025·0 cites·18 claims
- 1181US2025230218A1Pdl1 peptides for use in cancer vaccinesIO BIOTECH APS·Filed 2024·Application pending·0 cites
- 1279US12187782B2PDL1 peptides for use in cancer vaccinesIO BIOTECH APS·Filed 2022·Granted Jan 7, 2025·0 cites·5 claims
- 1379US9669078B2PD-L1 based immunotherapyHERLEV HOSPITAL·Filed 2012·Granted Jun 6, 2017·5 cites·15 claims
- 1478US12496333B2Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereofIO BIOTECH APS·Filed 2022·Granted Dec 16, 2025·0 cites·14 claims
- 1578US2024167013A1Immunogenic arginase peptidesIO BIOTECH APS·Filed 2023·Application pending·0 cites
- 1678US2022202922A1Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2022·Application pending·0 cites
- 1777US7892559B2Survivin-derived peptides and use thereofSURVAC APS·Filed 2003·Granted Feb 22, 2011·8 cites·2 claims
- 1877US2025205318A1Arginase1 polypeptidesIO BIOTECH APS·Filed 2024·Application pending·0 cites
- 1976US7842294B2Proteins belonging to the Bcl-2 family and fragments thereof, and their use in cancer patientsSURVAC APS·Filed 2004·Granted Nov 30, 2010·10 cites·53 claims
- 2075US10258678B2Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2016·Granted Apr 16, 2019·1 cites·13 claims
- 2175US2025319159A1Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2025·Application pending·0 cites
- 2274US2024052053A1Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)IO BIOTECH APS·Filed 2023·Application pending·0 cites
- 2373US12234288B2Immunogenic arginase 2 polypeptidesIO BIOTECH APS·Filed 2019·Granted Feb 25, 2025·0 cites·7 claims
- 2472US12194081B2ARGINASE1 polypeptidesIO BIOTECH APS·Filed 2019·Granted Jan 14, 2025·0 cites·8 claims
- 2572US7687465B2Therapeutic cancer vaccineSURVAC APS·Filed 2004·Granted Mar 30, 2010·4 cites·9 claims
- 2666USRE48522ESurvivin-derived peptides and uses thereofSURVAC APS·Filed 2018·Granted Apr 20, 2021·0 cites·16 claims
- 2766US2019247480A1RhoC-Based ImmunotherapyRHOVAC APS·Filed 2019·Application pending·0 cites
- 2866US2025161422A1Arginase 2 vaccineIO BIOTECH APS·Filed 2023·Application pending·0 cites
- 2965US11878053B2Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereofIO BIOTECH APS·Filed 2020·Granted Jan 23, 2024·0 cites·6 claims
- 3065US2022257741A1Combination therapy for cancerIO BIOTECH APS·Filed 2021·Application pending·0 cites
- 3162US9534030B2Survivin-derived peptides and uses thereofSURVAC APS·Filed 2012·Granted Jan 3, 2017·0 cites·3 claims
- 3262US9163077B2RhoC-based immunotherapyANDERSEN MADS HALD·Filed 2008·Granted Oct 20, 2015·0 cites·15 claims
- 3359US2025388674A1Immunogenic arginase 2 polypeptidesIO BIOTECH APS·Filed 2025·Application pending·0 cites
- 3457US10736950B2Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereofHERLEV HOSPITAL·Filed 2015·Granted Aug 11, 2020·0 cites·13 claims
- 3557US2020024324A1New pdl2 compoundsIO BIOTECH APS·Filed 2017·Application pending·0 cites
- 3656US8318174B2Survivin-derived peptides and use thereofSTRATEN EVIND PER THOR·Filed 2004·Granted Nov 27, 2012·1 cites·38 claims
- 3755US2020299401A1Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)IO BIOTECH APS·Filed 2018·Application pending·0 cites
- 3855US2024307516A1Combination therapy for cancerIO BIOTECH APS·Filed 2021·Application pending·0 cites
- 3955US2019343940A1Combination therapy against cancerIO BIOTECH APS·Filed 2017·Application pending·0 cites
- 4052US2020339659A1Pdl1 peptides for use in cancer vaccinesIO BIOTECH APS·Filed 2017·Application pending·0 cites
- 4149US2022315634A1Tgf-beta vaccineIO BIOTECH APS·Filed 2020·Application pending·0 cites
- 4246US2016008448A1Rhoc-based immunotherapyRHOVAC APS·Filed 2015·Application pending·0 cites
- 4346US2004210035A1Survivin-derived peptides and use thereofFiled 2003·Application pending·0 cites
- 4443US2011091489A1Survivin peptide vaccineSURVAC APS·Filed 2006·Application pending·0 cites
- 4540US2019328857A1Calr and jak2 vaccine compositionsIO BIOTECH APS·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mads Hald Andersen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →